



## Corrigendum

## Corrigendum to “Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma” [Eur J Canc 157 (2021) 250–258]



Alice Baggi <sup>a</sup>, Pietro Quaglinò <sup>b</sup>, Marco Rubatto <sup>b</sup>, Roberta Depenni <sup>c</sup>, Michele Guida <sup>d</sup>, Paolo Antonio Ascierto <sup>e</sup>, Claudia Trojaniello <sup>e</sup>, Paola Queirolo <sup>v</sup>, Maristella Saponara <sup>f</sup>, Ketty Peris <sup>g</sup>, Francesco Spagnolo <sup>h</sup>, Luca Bianchi <sup>i</sup>, Federica De Galitiis <sup>j</sup>, Maria Concetta Potenza <sup>k</sup>, Ilaria Proietti <sup>k</sup>, Riccardo Marconcini <sup>l</sup>, Andrea Botticelli <sup>m</sup>, Vito Barbieri <sup>n</sup>, Lisa Licitra <sup>o</sup>, Salvatore Alfieri <sup>p</sup>, Corrado Ficorella <sup>q,r</sup>, Alessio Cortellini <sup>q,s</sup>, Maria Concetta Fagnoli <sup>q,r</sup>, Teresa Troiani <sup>t</sup>, Luca Tondulli <sup>u</sup>, Manuel Zamparini <sup>a</sup>, Paolo Bossi <sup>a,\*</sup>

<sup>a</sup> University of Brescia, Department of Medical-Surgical Specialties, Radiological Sciences and Public Health, Medical Oncology, ASST-Spedali Civili, Brescia, Lombardia, Italy

<sup>b</sup> University of Turin, Dermatologic Clinic, Department of Medical Sciences Torino, Piemonte, Italy

<sup>c</sup> Università degli Studi di Modena e Reggio Emilia, Department of Oncology, Hematology, Modena, Emilia-Romagna, Italy

<sup>d</sup> IRCCS Istituto Oncologico di Bari Giovanni Paolo II, Oncology Department, Bari, Puglia, Italy

<sup>e</sup> Unit of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Campania, Italy

<sup>f</sup> IEO, Division of Medical Oncology for Melanoma, Sarcoma and Rare Tumors, Milano, Lombardia, Italy

<sup>g</sup> Università Cattolica del Sacro Cuore Campus di Roma, Institute of Dermatology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Lazio, Italy

<sup>h</sup> IRCCS Ospedale Policlinico San Martino, Skin Cancer Unit, Genova, Liguria, Italy

<sup>i</sup> University of Rome Tor Vergata, Dermatologic Unit, Department of Systems Medicine, Roma, Lazio, Italy

<sup>j</sup> Istituto Dermopatico dell'Immacolata IRCCS, Roma, Lazio, Italy

<sup>k</sup> Sapienza University of Rome, Dermatology Unit “Daniele Innocenzi”, Department of Medical-Surgical Sciences and Biotechnologies Polo Pontino, Terracina, Italy

<sup>l</sup> Azienda Ospedaliero Universitaria Pisana, Medical Oncology Unit, Pisa, Italy

<sup>m</sup> Sapienza University of Rome, Clinical and Molecular Department, Umberto I Policlinico di Roma, Roma, Lazio, Italy

<sup>n</sup> Azienda Ospedaliera di Catanzaro Pugliese Ciaccio, U.O. Oncologia, Catanzaro, Calabria, Italy

<sup>o</sup> Fondazione IRCCS Istituto Nazionale dei Tumori, Head and Neck Cancer Medical Oncology 3 Department, University of Milan, Department of Hematology and Oncology, Milano, Lombardia, Italy

<sup>p</sup> Fondazione IRCCS Istituto Nazionale dei Tumori, Head and Neck Cancer Medical Oncology 3 Department, Milano, Lombardia, Italy

<sup>q</sup> University of L'Aquila Department of Clinical Sciences and Applied Biotechnology, L'Aquila, Abruzzo, Italy

DOI of original article: <https://doi.org/10.1016/j.ejca.2021.08.018>.

\* Corresponding author: Medical Oncology, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health University of Brescia, ASST-Spedali Civili, Piazzale Spedali Civili 1, 25123, Brescia, Italy.

E-mail address: [paolo.bossi@unibs.it](mailto:paolo.bossi@unibs.it) (P. Bossi).

<https://doi.org/10.1016/j.ejca.2022.02.027>

0959-8049/© 2022 Elsevier Ltd. All rights reserved.

<sup>r</sup> San Salvatore Hospital, Medical Oncology, L'Aquila, Abruzzo, Italy

<sup>s</sup> Imperial College London, Department of Surgery and Cancer, London, UK

<sup>t</sup> University of Campania Luigi Vanvitelli, Medical Oncology, Department of Precision Medicine, Napoli, Campania, Italy

<sup>u</sup> Integrated University Hospital of Verona, Oncology Department, University Hospital of Verona, Verona, Veneto, Italy

<sup>v</sup> Division of Melanoma, Sarcomas and Rare Tumors, IEO, European Institute of Oncology, IRCCS, Milan, Italy

The authors regret that some Author information was incorrectly given in the published article. Author Manuel Zamparini was missed in the Author list, and the listed affiliation for Paola Queirolo was incorrect. The full and correct details for the Authors are:

Paola Queirolo  
Division of Melanoma, Sarcomas and Rare Tumors, IEO,  
European Institute of Oncology, IRCCS, Milan, Italy

Manuel Zamparini

University of Brescia, Department of Medical-Surgical Specialties, Radiological Sciences and Public Health, Medical Oncology, ASST-Spedali Civili, Brescia, Lombardia, Italy

The Authors also note that values in the first column of Table 4 were mistakenly reversed for 'Antibiotic intake (within 1 month before therapy)' and 'Haemoglobin'. The correct table in full is given here.

The authors would like to apologise for any inconvenience caused.

Table 4

Association between baseline factors with cemiplimab activity (CR + PR vs. SD + PD), multivariate-analysis.

Multivariate Factor	Event: SD/PD		P value
	OR	95%CI	
<b>Site 1</b>			0.075
Head and neck	1		
Others	3.445	0.883–13.446	
<b>Antibiotic intake (within 1 month before therapy)</b>			0.220
Yes	1		
No	0.194	0.014–2.665	
<b>Site of irradiation</b>			0.090
T	1		
N ± T	3.027	0.840–10.912	
<b>Hemoglobin</b>			0.826
>12	1		
≤12	1.166	0.296–4.586	